Viatris (VTRS)
(Delayed Data from NSDQ)
$11.70 USD
+0.20 (1.74%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $11.70 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Price, Consensus and EPS Surprise
VTRS 11.70 +0.20(1.74%)
Will VTRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VTRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTRS
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Here's Why You May Invest in Theravance (TBPH) Stock Now
VTRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for VTRS
Viatris 2023 Sustainability Report: Building Access Through a Global and Flexible Supply Chain
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth
Viatris (VTRS) Receives a Buy from Jefferies
Viatris reinstated with a Buy at Jefferies
Viatris 2023 Sustainability Report: Our Strategy and Model for Sustainable Access to Medicine